Rigel Pharmaceuticals Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)1.12 Intrinsic Value Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet. Market Price $46.97Price as of 1 Oct 2026 Data confidenceNot applicable Market Cap $877.4M Enterprise Value $861.6M Shares Outstanding 20.3M diluted Moat Rating Wide Next Earnings Date3 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Rigel Pharmaceuticals has successfully transitioned from a cash-burning clinical-stage biotech into a commercial-stage specialty pharmaceutical company with a growing portfolio of targeted therapies. The company's financial profile has significantly improved, characterized by robust year-over-year product sales growth, positive net income, and a solid cash position. While 2026 is viewed as a transition year with increased R&D and commercial expenses due to pipeline advancements and new product launches, the underlying commercial execution of its core products (Tavalisse, Gavreto, and Rezlidhia) combined with the newly licensed breast cancer drug Veppanu provides a strong foundation for long-term value creation. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$40.00 Mean target$54.20 High · most bullish analyst$81.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $38.0015% Commercial sales plateau due to intense competition in the AML and lung cancer spaces, while seasonal reimbursement pressures persist. Higher-than-expected commercialization expenses for Veppanu and R&D costs for R289 erode profitability, leading to a net loss for the year and downward pressure on the stock. Base CaseCentral scenario $54.2060% Matches the consensus meanRigel achieves its full-year 2026 revenue guidance of $275 million to $290 million, driven by steady double-digit growth in net product sales. The company maintains full-year profitability while funding its clinical pipeline, including the R289 MDS program and the transition of Veppanu. Valuation multiples expand moderately as the market recognizes the sustainability of its commercial cash flows. Bull CaseUpside scenario $81.0025% Accelerated adoption of Tavalisse, Gavreto, and Rezlidhia exceeds expectations, while the launch of Veppanu in the US captures significant market share in the second-line ER+/HER2- breast cancer market. Additionally, positive top-line Phase 1b data for R289 in lower-risk MDS triggers a lucrative licensing deal or rapid progression to Phase 2, driving substantial upward re-rating. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |